Methods for preventing and treating peripheral neuropathy by administering desmethylselegiline delivery compositions
OwnerCheryl D. Blume, Anthony R. DiSantoinventors
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to methods for alleviating the symptoms associated with peripheral neuropathy by administering R(−)-desmethylselegiline, S(+) desmethylselegiline, or a combination of the two. The neuropathy may be the result of a genetically inherited condition, a systemic disease, or exposure to a toxic agent. The disclosure is also directed to a method for treating patients with cancer by administering a chemotherapeutic agent known to have a toxic affect on peripheral nerves together with R(−)-desmethylselegiline, S(+) desmethylselegiline, or a mixture of the two.
Claims62
A method of preventing or treating peripheral neuropathy caused by a toxic agent in a subject in need of such prevention or treatment, comprising:
- administering R(−)-desmethylselegiline to the subject in an amount sufficient to prevent, reduce, or eliminate one or more of the symptoms associated with the peripheral neuropathy.
A method of treating a subject for peripheral neuropathy caused by a genetically inherited condition, comprising:
- administering R(−)-desmethylselegiline to the subject in an amount sufficient to reduce or eliminate one or more of the symptoms associated with the peripheral neuropathy.
A method of preventing or treating a subject for peripheral neuropathy caused by a systemic disease, comprising:
- administering R(−)-desmethylselegiline to the subject in an amount sufficient to reduce or eliminate one or more of the symptoms associated with the peripheral neuropathy.
A method for treating a subject with cancer comprising:
- a) administering to the subject a chemotherapeutic agent known to have a toxic effect on peripheral nerves, wherein the chemotherapeutic agent is administered at a dose effective at slowing the progression of the cancer;
- and
- b) concurrently administering R(−)-desmethylselegiline to the subject at a dose effective at reducing or eliminating the peripheral neuropathy associated with the chemotherapeutic agent.
A method of preventing or treating a subject for peripheral neuropathy caused by compression, trauma, or entrapment, comprising:
- administering R(−)-desmethylsclcgiline to the subject in an amount sufficient to reduce or eliminate one or more of the symptoms associated with the peripheral neuropathy.
A method of preventing or treating large-fiber peripheral neuropathy in a subject in need of such prevention or treatment, comprising:
- administering R(−)-desmethylselegiline to the subject in an amount sufficient to prevent, reduce, or eliminate one or more of the symptoms associated with the large-fiber peripheral neuropathy.
A method of preventing or treating small-fiber peripheral neuropathy in a subject in need of such prevention or treatment, comprising:
- administering R(−)-desmethylselegiline to the subject in an amount sufficient to prevent, reduce, or eliminate one or more of the symptoms associated with the small-fiber peripheral neuropathy.
A method of preventing or treating a subject for autonomic peripheral neuropathy in a subject in need of such prevention or treatment, comprising:
- administering R(−)-desmethylselegiline to the subject in an amount sufficient to reduce or eliminate one or more of the symptoms associated with the autonomic peripheral neuropathy.
A method of preventing or treating a motor neuron disease in a subject in need of such prevention or treatment, comprising:
- administering R(−)-desmethylselegiline to the subject in an amount sufficient to reduce or eliminate one or more of the symptoms associated with the motor neuron disease.
A pharmaceutical composition, comprising:
- a) R(−)-desmethylselgiline;
- and
- b) a second therapeutic agent useful in the treatment of peripheral neuropathy.
Dependencies are inferred from the claim text.